uniQure N.V. announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board?s Audit Committee, has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial. Since February 2019, Ms. Jacques has served as the Chief Executive Officer of Enzyvant Therapeutics Inc. From August 2017 to February 2019, she served as the Senior Vice President and Global Complement Franchise Head at Alexion Pharmaceuticals Inc.